跳至主要内容
临床试验/NCT03090672
NCT03090672Unknown不适用

Use of Cellular and Biocellular Therapy in Musculoskeletal Pain, Dysfunction, Degenerative or Inflammatory Disease

Robert W Alexander, MD1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2017年3月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
300
试验地点
1
主要终点
Participants with complications

研究概览

简要总结

Musculoskeletal disorders and degeneration represent injuries or pain in the body's joint ligaments, tendons, muscles, nerves, and skeletal elements that support extremities, spine and related tissues. Direct injuries and aging contribute to breakdown and inflammation of these tissues, leading to debilitation and loss of function in these areas. This has major impact on quality of life, occupational/recreation limitations, and psychosocial implications.

Many therapies have been employed including medications, physical therapy, occupational therapy, and a variety of surgical interventions each of which have distinct limitations, often covering the issues versus providing actual healing and return to function. Many reports are now available utilizing self-healing options which include use of stem/stromal cellular therapy or biocellular treatments (either from adipose or marrow) using targeted placement of cells, matrix and platelet concentrates. Termed cellular or Biocellular therapy (typically optimized using ultrasound guidance). It is proposed that use of cellular isolates or cell-stroma derived from the largest deposit of these cells (adipose greater than marrow), may use in conjunction with targeted placement or as a stand alone methodology intravascular use.

This study is designed as a interventional means to examine the safety and efficacy of the use of cellular and tissue stromal vascular fraction in musculoskeletal pain, dysfunction degeneration or inflammatory disorders.

详细描述

Musculoskeletal disorders and degeneration represent injuries or pain in the body's joint ligaments, tendons, muscles, nerves, and skeletal elements that support extremities, spine and related tissues. Direct injuries and aging contribute to breakdown and inflammation of these tissues, leading to debilitation and loss of function in these areas. This has major impact on quality of life, occupational/recreation limitations, and psychosocial implications.

Many therapies have been employed including medications, physical therapy, occupational therapy, and a variety of surgical interventions each of which have distinct limitations, often covering the issues versus providing actual healing and return to function. Many reports are now available utilizing self-healing options which include use of stem/stromal cells (either from adipose or marrow) using targeted placement of cells, matrix and platelet concentrates. This is termed Biocellular therapy, and typically is optimized by use of ultrasound guidance. It is proposed that use of cellular isolates derived from the largest deposit of these cells (adipose greater than marrow), may use in conjunction with targeted placement or as a stand alone methodology of parenteral use.

This study is designed as a interventional means to examine the safety and efficacy of the use of cellular stromal vascular fraction (cSVF) in musculoskeletal pain, dysfunction degeneration or inflammatory disorders. The important cellular components represent, not the adipocyte, but the heterogeneous cell group associated with the peri-vasculature. The group does include certain cells referred to as "stem" or "stromal" cells, and are considered key elements of cellular and biocellular treatments. The carrier microvascular tissue, adipose, has been shown to not participate in wound healing or cellular replacement per se. It is well established that those perivascular (adventitial) cell types are found in essentially all tissues of the body, but in highest numbers in the easily accessed depots with the subdermal fat. It is proposed that areas of these groups are responded to as a result of "signaling" to permit a chemotactic request for needed growth factors and cytokines which effectively contribute to the healing capability at failing or damaged sites. This Trial will investigate the safety/efficacy of either combining specific targeting (ultrasound) with and/or without systemic parenteral route introduction.

This study includes closed syringe, disposable microcannula harvesting of subdermal fat tissues for obtaining the native perivascular stromal elements (extracellular matrix (ECM) and periadventitial cells shown to be multipotent (in potentials), incubation, digestion and isolation of cSVF. This isolated and concentration of stem/stromal cellular pellet (without actual extracellular matrix or stromal scaffolding elements) is then suspended in 500 cc sterile Normal Saline (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured at intervals (both severe and non-severe categories) and by ultrasound and imaging studies.

Biocellular treatments are defined as use of tissue stromal vascular fraction (tSVF) obtained within adipose tissue complex (ATC), combined with high density platelet rich plasma (HD PRP) concentrated from standard blood draw. Concentration in FDA approved platelet concentrate devices to achieve levels of >4 times patient's own measured baseline levels. Such concentrates have been shown to provide important growth factors and cytokines (signal proteins) naturally involved in wound healing and repair functions. A form of Cell-Enriched Biocellular Therapy (CEBT) is available as a component of this study, in which the tSVF + HD PRP can be enhanced in cellular numbers via the process of isolating and concentrating cSVF discussed above. Many small case series and case reports have been published in the peer reviewed medical literature which suggest that these interventions are both safe and effective at relieving musculoskeletal disorders included in the study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with documented inflammatory, autoimmune (rheumatoid arthritis (RA), degeneration of musculoskeletal system
  • No systemic disorders which, in the opinion of the principal investigators or provider, would disqualify from being safely able to undergo needed procedures
  • Able to provide informed consent
  • Patient having adequate donor adipose (fat) tissue
  • Patient mature enough to tolerate the needed procedures

排除标准

  • Systemic or psychological impairment which would preclude patient tolerance and understanding of procedures and follow up
  • Patients with known active cancer and chemotherapy or radiation therapy
  • Patients with ongoing active infections
  • High dose steroid users or use of injections of corticoid steroids within a six month timeframe
  • Opiate addition or in treatment program for withdrawal
  • History of severe traumatic brain injuries
  • If, in the opinion of providers, the patient will not be able to fully cooperate or complete the study and its follow up

研究组 & 干预措施

tSVF + PRP + cSVF Enrichment Arm 2

Experimental

tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)

干预措施: Cellular Stromal Vascular Fraction (Procedure)

Normal Saline IV + cSVF Arm 3

Experimental

Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction

干预措施: Normal Saline (Drug)

tSVF + PRP Arm1

Experimental

Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate

干预措施: Tissue Stromal Vascular Fraction (Procedure)

tSVF + PRP Arm1

Experimental

Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate

干预措施: Platelet Rich Plasma (Biological)

tSVF + PRP + cSVF Enrichment Arm 2

Experimental

tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)

干预措施: Tissue Stromal Vascular Fraction (Procedure)

tSVF + PRP + cSVF Enrichment Arm 2

Experimental

tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)

干预措施: Platelet Rich Plasma (Biological)

Normal Saline IV + cSVF Arm 3

Experimental

Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction

干预措施: Cellular Stromal Vascular Fraction (Procedure)

结局指标

主要结局

Participants with complications

时间窗: 1 month

Adverse and Severe Adverse Events Reports

次要结局

  • Change from baseline visual analog pain score(6 months, 1 year, 2 year)
  • Change from baseline of imaging if required for study entry(baseline, 1 year)
  • Change from baseline quality of life level (QoL Questionnaire)(6 months, 12 months)
  • Change from baseline of limitation of activities (Functional analysis of range of motion)(baseline, 6 months, 1 year)

研究者

发起方
Robert W Alexander, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Robert W Alexander, MD

Principal Investigator

Regeneris Medical

研究点 (1)

Loading locations...

相似试验

Cellular & Biocellular Regenerative Therapy in... | 临床试验